Speaking against the use of COVID mRNA vaccines, experts pointed out the significant increase in the risk of cardiac-related death, especially in males aged 18 to 39. They further advised that people with certain heart-related ailments should consult their physician before taking these jabs.
Florida Surgeon General Dr Joseph A Ladapo said in a tweet, “Today, we released an analysis on COVID-19 mRNA vaccines the public needs to be aware of. This analysis showed an increased risk of cardiac-related death among men 18-39. FL will not be silent on the truth.”
The analysis was conducted by the Florida Department of Health (Department) through a self-controlled case series, which is a technique originally developed to evaluate vaccine safety. The study found a sharp 84% increase in the relative incidence of cardiac-related death among males 18-39 years old within 28 days following mRNA vaccination.
The study suggests that patients with pre-existing cardiac conditions, such as myocarditis and pericarditis, should be extra cautious when considering vaccination and discuss it with their healthcare provider.
“Studying the safety and efficacy of any medications, including vaccines, is an important component of public health,” said Surgeon General Dr Joseph Ladapo. “Far less attention has been paid to safety and the concerns of many individuals have been dismissed – these are important findings that should be communicated to Floridians.”
Meanwhile, India’s first mRNA Covid-19 vaccine – Gennova’s GEMCOVAC-19 will be available soon for emergency use. The company has conducted phase 2 and phase 3 data trials on 4000 participants to evaluate vaccine safety, immunogenicity and tolerability. India’s drug regulator Drugs controller general of India (DCGI) is expected to give EUA to the vaccine soon.
According to officials at Gennova, the trial data showed that the vaccine was safe and well-tolerated. Immunogenicity measured at 2 weeks post-dose showed that GEMCOVAC-19 is non-inferior to Covishield. The two-dose vaccine will have to be administered intramuscularly, 28 days apart.
